The Investor
08 Sep 2026, 16:39
Johnson & Johnson to Present Phase 3 CAPLYTA Data at 2026 Psych Congress
Johnson & Johnson (NYSE: JNJ) will present 24 abstracts spanning its neuropsychiatry portfolio at the 2026 Psych Congress Annual Meeting, scheduled for September 15-19 in New Orleans.
A key focus will be the first presentation of pivotal Phase 3 data evaluating CAPLYTA (lumateperone) for the acute treatment of manic episodes, including episodes with mixed features, associated with bipolar I disorder. Additional CAPLYTA research will cover bipolar depression and major depressive disorder, including depressive symptoms, remission, patient subgroups and metabolic outcomes.
The company will also present new analyses of SPRAVATO (esketamine) examining its impact on anhedonia, a core symptom of depression associated with poorer treatment outcomes.
Johnson & Johnson’s broader neuroscience pipeline will also be represented. Phase 3 clinical trial data for seltorexant in major depressive disorder with insomnia symptoms are scheduled for presentation, alongside real-world research examining the disease burden and management of these patients.
Additional studies will focus on long-acting injectable treatments for schizophrenia, including hospitalization, relapse risk and patient treatment satisfaction.
The upcoming presentations highlight Johnson & Johnson’s efforts to expand its presence across mood disorders and other high-burden neuropsychiatric conditions, with the pivotal CAPLYTA bipolar mania results representing one of the most closely watched updates.
Johnson & Johnson (NYSE: JNJ) will present 24 abstracts spanning its neuropsychiatry portfolio at the 2026 Psych Congress Annual Meeting, scheduled for September 15-19 in New Orleans.
A key focus will be the first presentation of pivotal Phase 3 data evaluating CAPLYTA (lumateperone) for the acute treatment of manic episodes, including episodes with mixed features, associated with bipolar I disorder. Additional CAPLYTA research will cover bipolar depression and major depressive disorder, including depressive symptoms, remission, patient subgroups and metabolic outcomes.
The company will also present new analyses of SPRAVATO (esketamine) examining its impact on anhedonia, a core symptom of depression associated with poorer treatment outcomes.
Johnson & Johnson’s broader neuroscience pipeline will also be represented. Phase 3 clinical trial data for seltorexant in major depressive disorder with insomnia symptoms are scheduled for presentation, alongside real-world research examining the disease burden and management of these patients.
Additional studies will focus on long-acting injectable treatments for schizophrenia, including hospitalization, relapse risk and patient treatment satisfaction.
The upcoming presentations highlight Johnson & Johnson’s efforts to expand its presence across mood disorders and other high-burden neuropsychiatric conditions, with the pivotal CAPLYTA bipolar mania results representing one of the most closely watched updates.
